% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Platen:258697,
      author       = {Platen, Moritz and Flessa, Steffen and Teipel, Stefan and
                      Rädke, Anika and Scharf, Annelie and Mohr, Wiebke and
                      Buchholz, Maresa and Hoffmann, Wolfgang and Michalowsky,
                      Bernhard},
      title        = {{I}mpact of low-value medications on quality of life,
                      hospitalization and costs - {A} longitudinal analysis of
                      patients living with dementia.},
      journal      = {Alzheimer's and dementia},
      volume       = {19},
      number       = {10},
      issn         = {1552-5260},
      address      = {Hoboken, NJ},
      publisher    = {Wiley},
      reportid     = {DZNE-2023-00670},
      pages        = {4520 - 4531},
      year         = {2023},
      abstract     = {This study aimed to analyze the impact of low-value
                      medications (Lvm), that is, medications unlikely to benefit
                      patients but to cause harm, on patient-centered outcomes
                      over 24 months.This longitudinal analysis was based on
                      baseline, 12 and 24 months follow-up data of 352 patients
                      with dementia. The impact of Lvm on health-related quality
                      of life (HRQoL), hospitalizations, and health care costs
                      were assessed using multiple panel-specific regression
                      models.Over 24 months, 182 patients $(52\%)$ received Lvm at
                      least once and 56 $(16\%)$ continuously. Lvm significantly
                      increased the risk of hospitalization by $49\%$ (odds ratio,
                      confidence interval [CI] $95\%$ 1.06-2.09; p = 0.022),
                      increased health care costs by €6810 (CI $95\%$
                      -707€-14,27€; p = 0.076), and reduced patients' HRQoL (b
                      = -1.55; CI $95\%$ -2.76 to -0.35; p = 0.011).More than
                      every second patient received Lvm, negatively impacting
                      patient-reported HRQoL, hospitalizations, and costs.
                      Innovative approaches are needed to encourage prescribers to
                      avoid and replace Lvm in dementia care.Over 24 months, more
                      than every second patient received low-value medications
                      (Lvm). Lvm negatively impact physical, psychological, and
                      financial outcomes. Appropriate measures are needed to
                      change prescription behaviors.},
      keywords     = {Humans / Quality of Life / Health Care Costs /
                      Hospitalization / Dementia: drug therapy / Alzheimer's
                      disease (Other) / dementia (Other) / health care costs
                      (Other) / health care resources (Other) / health-related
                      quality of life (Other) / hospitalization (Other) /
                      low-value care (Other)},
      cin          = {AG Hoffmann / AG Teipel / AG Thyrian / AG Michalowsky ; AG
                      Michalowsky},
      ddc          = {610},
      cid          = {I:(DE-2719)1510600 / I:(DE-2719)1510100 /
                      I:(DE-2719)1510800 / I:(DE-2719)5000067},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36905286},
      doi          = {10.1002/alz.13012},
      url          = {https://pub.dzne.de/record/258697},
}